Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
View Patent ↗Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.
1. A method for administering a therapeutically effective amount of a daily dose of about 300 mg to about 2000 mg of acamprosate to a subject suffering from alcohol dependence, comprising administering to the subject acamprosate or a pharmaceutically acceptable salt thereof dispersed in a gastric retained dosage form to the subject in which a fed mode has been induced and wherein the dosage form comprises a single polymer matrix comprising at least one swellable hydrophilic polymer that swells in a dimensionally unrestrained manner by imbibing water to increase its size to promote gastric retention of the dosage form in the stomach of the subject, wherein upon contact with aqueous fluid, at least about 80% of the acamprosate in the extended release portion of the dosage form is released by the dosage form over a period of at least about 5 hours, and wherein upon administration to the subject, the gastric retained dosage form provides a mean AUC of plasma acamprosate which is at least 50% greater than the mean AUC of plasma acamprosate provided by an immediate release (IR) dosage form or pharmaceutically acceptable salt thereof equal to or more than the dose of acamprosate in the gastric retained dosage form.
2. The method of claim 1 , wherein the gastric retentive dosage form provides a mean C max of plasma acamprosate which is about 60% to 70% of the mean C max of plasma acamprosate provided by an IR dosage form which contains a dose of acamprosate or pharmaceutically acceptable salt thereof equal to or less than the dose of acamprosate in the gastric retentive dosage form.
3. The method of claim 1 , wherein the gastric retained dosage form provides a T max which is about 3 hours to 8 hours greater than the T max provided by an IR dosage form which contains a dose of acamprosate or pharmaceutically acceptable salt thereof equal to or less than the dose of acamprosate in the gastric retentive dosage form.
4. The method of claim 1 , wherein said dose is administered with a meal.
5. The method of claim 1 , wherein the daily dose is administered as a single dose per a 24 hour period.
6. The method of claim 1 , wherein the daily dose is administered as two doses per a 24 hour period.